Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma
- 18 August 2026
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (11) , 1395-1403
Abstract
Objectives: Spread through air spaces (STAS) is a poor prognostic pathological feature recently included as a histological factor in the ninth edition of the TNM (tumor, node, and metastasis) classification. However, its clinical significance in lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations remains unclear. Here, we aimed to evaluate the clinical significance of STAS according to EGFR mutation status. Methods: We retrospectively reviewed 347 patients with completely resected pathological stage 0–IIIB lung adenocarcinoma who were evaluated for both STAS and EGFR mutations between 2015 and 2022. We investigated the association between clinicopathological features and STAS and analyzed its prognostic relevance based on EGFR mutation status. Results: STAS and EGFR mutations were present in 85 (24.5%) and 178 (51.3%) patients, respectively. In patients with EGFR-mutated lung adenocarcinoma, STAS was significantly more prevalent in those with exon 19 deletions than those with the L858R mutation (P = .012). STAS was significantly markedly associated with poorer recurrence-free and overall survival in patients both with (P < .001 and P < .001, respectively) and without (P = .003 and P = .023, respectively) EGFR mutations. Multivariable analysis revealed that STAS was an independent prognostic factor for recurrence-free and overall survival in patients with EGFR mutations (P < .001 and P = .020, respectively). However, STAS was not an independent predictor in patients without EGFR mutations. Conclusions: STAS is a key pathological feature of lung adenocarcinoma and holds considerable clinical relevance, particularly in EGFR-mutated lung adenocarcinoma.Keywords
This publication has 35 references indexed in Scilit:
- Anaplastic Lymphoma Kinase Rearrangement and Tumor Spread Through Air Spaces Is Associated with Worse Clinical Outcomes for Resected Stage IA Lung AdenocarcinomaClinical Lung Cancer, 2025
- Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR MutationsClinical Lung Cancer, 2024
- Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung CancerJAMA Network Open, 2023
- Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2Clinical Lung Cancer, 2023
- Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air SpacesClinical Lung Cancer, 2022
- Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer CasesThe Annals of Thoracic Surgery, 2021
- Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisThe Annals of Thoracic Surgery, 2019
- Prognostic Impact of Tumor Spread Through Air Spaces in Non-small Cell Lung Cancers: a Meta-Analysis Including 3564 PatientsPathology and Oncology Research, 2019
- Computed tomography features of resected lung adenocarcinomas with spread through air spacesThe Journal of Thoracic and Cardiovascular Surgery, 2018
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016